Avance Clinical, a global Contract Research Organization, has signed Memorandums of Understanding with four premier Taiwanese medical institutions, strengthening its GlobalReady model for biotech companies.

The NIH is investing $30 million to launch the CARE for Health network, aimed at integrating clinical research with community-based primary care.

Lokavant's AI analysis highlights how trial planning decisions can unintentionally skew conclusions, impacting the reliability of study results.

Mission Bio presented new data at ASH 2024 demonstrating the Tapestri platform's utility in integrating genomic, immunophenotypic, and clonotypic assessment for multiple myeloma.

A groundbreaking study by researchers at the University of Bristol and Federal University of São Paulo reveals that regular aerobic exercise significantly reduces key Alzheimer's disease markers, including a 76% reduction in amyloid plaques and 63% decrease in tau tangles. The research provides compelling evidence for exercise's neuroprotective effects and potential role in Alzheimer's prevention strategies.

A new clinical trial published in Lancet Psychiatry demonstrates that mindfulness-based cognitive therapy (MBCT) significantly improves symptoms in patients with difficult-to-treat depression compared to standard care.

The FDA Omnibus Reform Act (FDORA) is reshaping clinical trials by mandating diversity action plans, encompassing factors beyond race and ethnicity, such as gender identity and socioeconomic status.

The University of California, San Francisco has secured a $75.4 million grant from the National Institute on Aging to conduct a groundbreaking platform trial testing multiple drugs for progressive supranuclear palsy.

Rice University received a $34.9 million grant to develop ROGUE, a bioelectronic implant for type 2 diabetes and obesity treatment, designed to improve patient adherence.

The LOLA Project aims to revolutionize lung and colon cancer diagnosis in Andalusia by integrating liquid biopsies and advanced sequencing technologies.

A 35-year-old woman with stage 4 colon cancer achieved complete remission after receiving experimental CRISPR-Cas9 gene-edited immunotherapy at the University of Minnesota, marking an unprecedented outcome for advanced colorectal cancer.

A study by the University of Alabama at Birmingham reveals that an obesity drug can decrease the risk of Type 2 diabetes by 60%. The research highlights the effectiveness of a higher dose of the drug, Semaglutide, in weight loss and diabetes prevention, especially in Alabama where diabetes rates are significantly higher than the national average.

MedPacto partners with leading US institutions, including Stanford University and Case Western Reserve University, to conduct Phase 2 trial of vactosertib for pediatric osteosarcoma treatment.

Kane Biotech has received IRB approval from the University of Miami Health System to commence a clinical study of its DispersinB® Acne Cleanser for mild to moderate Acne Vulgaris.

A retrospective study of 20 patients with non-metastatic small cell carcinoma of the bladder (SCCB) showed a median overall survival of 65.3 months.

A systematic review evaluates the effectiveness of pharmacologic and nonpharmacologic interventions for treating suicidality in psychiatric inpatients, highlighting the need for larger, well-designed trials.

N-of-1 therapies are gaining traction as a promising approach for treating rare and ultra-rare diseases, offering individualized treatments tailored to a single patient's unique genetic and clinical profile.

Researchers from Imperial College London and Lund University found that early combination therapy with statins and ezetimibe significantly reduces the risk of subsequent heart attacks and death in cardiac patients.

New research from University of Bath and Lund University exposes significant transparency issues in the UK's voluntary pharmaceutical payment disclosure system, with £3.3 billion in research payments lacking recipient details.

West Virginia lawmakers passed a bill allowing clinical trials on opioid use disorder treatments, specifically comparing buprenorphine and methadone.